Zai Lab Limited (HKG:9688)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.45
+1.35 (4.98%)
Jun 5, 2025, 3:45 PM HKT
85.46%
Market Cap 30.71B
Revenue (ttm) 3.25B
Net Income (ttm) -1.96B
Shares Out n/a
EPS (ttm) -19.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,762,130
Average Volume 11,688,694
Open 28.00
Previous Close 27.10
Day's Range 27.95 - 29.65
52-Week Range 12.32 - 32.50
Beta 1.04
RSI 66.19
Earnings Date May 8, 2025

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 1,869
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9688
Full Company Profile

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD Financial Statements

News

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab Limited (NASDAQ: ZLAB) and NovoCure Limited (NASDAQ: NVCR) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic can...

2 days ago - Benzinga

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating z...

3 days ago - Business Wire

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor...

4 days ago - Business Wire

Zai Lab Announces Participation in Investor Conferences in June 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...

6 days ago - Business Wire

Zai Lab gets FDA fast track status for lung cancer treatment

Zai Lab's ZL-1310 receives FDA fast-track & orphan drug status for small cell lung cancer. Read more here.

16 days ago - Seeking Alpha

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the ...

17 days ago - Business Wire

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2025, along with recent product highlights and corpo...

4 weeks ago - Business Wire

Earnings Scheduled For May 8, 2025

Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...

4 weeks ago - Benzinga

Zai Lab Q1 2025 Earnings Preview

4 weeks ago - Seeking Alpha

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational...

5 weeks ago - Business Wire

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Ltd (NASDAQ: NVCR) reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents . Sales increased 12% year over year...

5 weeks ago - Benzinga

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating Z...

6 weeks ago - Business Wire

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New ...

6 weeks ago - Business Wire

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-ge...

2 months ago - Business Wire

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approval...

2 months ago - Seeking Alpha

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License...

3 months ago - Business Wire

Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB)

Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB)

3 months ago - GuruFocus

Zai Lab Announces Participation in Investor Conferences in March 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...

3 months ago - Business Wire

Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight

Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight

3 months ago - GuruFocus